Cardiac MRI study of heart health after Hodgkin lymphoma treatment
Part of Heart & circulation clinical trials.
This study looks at how certain blood-related “growth patterns” connect to long-term heart health after treatment for classical Hodgkin lymphoma. It may help doctors better predict who could develop heart problems and how to monitor them over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 7 years old when you join, so you can get an MRI without sedation
- You were diagnosed with classical Hodgkin lymphoma between ages 2 and 21
- You received a high enough total dose of a cancer drug related to doxorubicin (an “anthracycline”) during frontline treatment (≥ 200 mg/m² equivalent)
- You finished all cancer treatment at least 2 years before joining
- You can have a non-contrast cardiac MRI at the study site without sedation
- You do not have major heart disease or other serious heart problems that started before your Hodgkin diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
This study looks at how lymphoma treatment may affect thinking and memory years after therapy. It aims to understand and support long-term survivors.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
This study uses a special type of CT scan called spectral CT to see if chemotherapy drugs called anthracyclines can cause heart damage in people with certain lymphomas. The goal is to catch any heart problems early by imaging the heart before, during, and after treatment.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.